Apretude is a medicine approved by the FDA in 2021 to reduce the risk of contracting HIV through sexual contact, also known as pre-exposure prophylaxis (PrEP). PrEP is used to prevent the transmission ...
Today, the U.S. Food and Drug Administration approved Apretude (cabotegravir extended-release injectable suspension) for use in at-risk adults and adolescents weighing at least 35 kilograms (77 pounds ...
The application is supported by data from the phase 2b/3 HPTN 083 and HPTN 084 trials, which evaluated the efficacy and safety of Apretude for HIV PrEP. The Food and Drug Administration (FDA) has ...
The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. This medicine is new or being used differently. Please report side ...
The Food and Drug Administration (FDA) has approved the first injectable treatment for HIV pre-exposure prophylaxis, providing another option to help individuals at-risk avoid sexually transmitted HIV ...
Add Yahoo as a preferred source to see more of our stories on Google. In a large clinical trial assessing Apretude, ViiV Healthcare’s recently approved injectable drug, as a form of HIV prevention, ...
The federal Food and Drug Administration has approved Apretude (extended-release cabotegravir), the first long-acting injectable option for HIV prevention. The shots, which are administered by a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results